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INTRODUCTION
Following renal transplantation, the incidence of CMV infection varies from 52%
(18) to 91% (2). There are a number of putative risk factors which contribute to
cytomegalovirus infection after transplantation (Table 1). It is not clear how im-
portant each one is. The virus may either be introduced from an outside source to
produce a primary infection, or an endogenous infection may be activated to produce
a secondary infection. The latter type of infection occurs more frequently than the
former type. For example, Craighead et al. (8) found that 90% of the seropositive
recipients became infected, while only 47% ofthe seronegative became infected. Our
own rates, 80% and 59% (see below) are consistent with this experience. Kanich and
Craighead (18) pointed out in a retrospective autopsy study that only patients who
had received immunosuppressive agents (azathioprine, prednisone, azaserine, and
actinomycin C, in various combinations) became infected. Immunosuppressive drugs
may contribute to infection by facilitating reactivation or primary infection, but their
relative importance in these two types ofinfections is unknown.
In this paper we will review what is known about each risk factor(Table 1), present
some data from our laboratory regarding the role of transfused blood, the donated
kidney, and the host versus graft reaction (factors A3, A4, and B4), and estimate
quantitatively their roles in producing CMV infection. The role of immunosup-
pressive drugs (factor B2) is treated in greater detail in a separate communication
(11).
SOURCE OF VIRUS
There is no consensus as to how cytomegalovirus is usually transmitted. The
ubiquity of this infection, the higher rates ofinfection in lower socioeconomic strata
(27, 22), and the rapid acquisition ofinfection in young children and general increase
with age (29) are all observations consistent with transmission by close person-to-
person contact. Familial contacts of known virus excretors, or persons housed in an
institution as contrasted to those living at home, are at greater risk forinfection (33).
Weller (36) distinguishes the following modes of viral transmission: (i) Prenatal
transmission of the virus occurs from the mother transplacentally to the fetus,
usually but not exclusively following a pnmary infection ofthe mother. The pregnant
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TABLE 1
Risk Factors in Cytomegalovirus Infection
A. Source ofvirus (primary infection)
1. Outside environment
2. Contact with persons
3. Transfused blood
4. Donated kidney
B. Depression ofhost resistance
1. Renal failure
2. Immunosuppression by drugs
3. Immunosuppression by other methods
4. Host versus graft reaction
5. Graft versus host reaction
woman has been found to be a more frequent carrier of the virus than the non-
pregnant (25, 29). The fetus may also be infected by intrauterine transfusion. (ii)
Perinatal transmission may be acquired by passage through an infected birth canal or
shortly thereafter. Not only do pregnant women carry the virus in the cervix, but so
do postpartum women (9, 1). (iii) The immediate postnatal period is one of high rate
of acquisition of infection. Potential sources of infection include the cervical secre-
tions, milk (29, 9) and respiratory tract (4) ofthe mother and other contacts ofthe in-
fant. More recently CMV in the cervix was associated with venereal disease (15). It
has also been detected in semen of young men (20), in stools (6), and in transfused
blood (10). These findings suggest numerous additional potential sources for CMV
and that its modes of transmission may be protean. Like infectious mononucleosis it
may be a "kissing disease", transmitted by respiratory secretions. It may also be
transmitted as a venereal infection analogous to Herpes simplex Type II, or it may
be transmitted by contaminated urine or feces like an "enteric disease." Finally,
cytomegalovirus mononucleosis has been observed to occur in the adult frequently
following transfusions (16, 17).
The foregoing emphasizes the many possible human reservoirs for CMV. There is
no known environmental reservoir of CMV, nor has there been described an out-
break associated with a suspected contaminated environmental source. This possi-
bility exists whenever an agent is dispersed in large quantities from a bodily source,
such as urine, where the virus may be excreted for long periods oftime in concentra-
tions as high as 106 infectious particles/ml. Significant environmental reservoirs are
made less likely by the fact that this virus is quite labile.
No specific information is available concerning the infectivity of carriers ofCMV
for the renal transplant patientjust as there are no precisedata for natural infection.
Coulson et al. (5) describe an "epidemic" of "40-day fever" due to CMV in a renal
transplant population which lasted for 18 months. The likely source was considered
to be the close person-to-person contact in the renal dialysis unit, although the
precise site was not identified.
BLOOD AS A SOURCE OF VIRUS
Since the description of posttransfusion CMV mononucleosis (16, 17, 28, 12, 21)
and the report of Diosi et al. (10) that CMV was isolated from the leukocytes of two
out of 35 healthy donors, transfused blood has been implicated as a source ofinfec-
tive virus. This hypothesis is tested in various high risk populations elsewhere in this
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volume. The pertinent facts are: (i) Contrary to Diosi's findings (10), the frequency of
CMV isolation from the buffy coats of bloods used in this country is extremely low
(probably <0.1%) or nonexistent (26). This "negative" finding of course does not
rule out that certain donor populations are a hazard, or that inapparently or latently
infected buffy coats may exist, and are infectious in a susceptible subject. (ii) It is
possible that transfused blood cells may act in other ways (19). They are foreign cells
which incite a host versus graft response in the recipient. Donated lymphocytes may
also initiate a graft versus host reaction in the recipient. Either or both reactions may
activate or enhance latent virus in the donor cells or in the recipient. These possi-
bilities are discussed below.
The relationship of the amount ofblood transfused to CMV infection in a group of
46 renal transplant recipients is shown in Fig. 1. Infection is defined as isolation of
CMV from blood or urine and/or a fourfold increase in CF titer within 6 months of
transplantation. The mean number of units transfused for the entire group was 3.17
per patient. Figure 1a shows data for the entire group while Fig. lb considers the
subgroup of those who were initially seronegative. The CMV infection rates for the
entire group and for the seronegative subgroup were 54% (25/46) and 50% (16/32),
respectively. There is no discernable relationship between infection and number of
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FIG. 1. Relationship between units ofblood transfused to subsequent CMV infection in 46 renal trans-
plant recipients (a) and in those who were seronegativepreoperatively (b).
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units received during or after a transplant operation. Five of nine patients who
received no transfusions became infected, a rate (56%) comparable to that of the
group as a whole (54%). One patient received 8 units and remained uninfected.
Hence we see no evidence thatblood was a source ofCMV infection in our transplant
group. What other contributory role it may have played also could not be detected.
THE DONATED KIDNEY AS A SOURCE OF VIRUS
A suspected but unproven source of exogenous virus infecting the transplant
recipient is the grafted kidney itself (13, 23). Sporadic attempts to isolate the virus
from the grafted kidney have been unrewarding (3, 23). As a latent virus might not be
readily demonstrable, we undertook a study relying on the presence ofdetectable an-
tibody in the donor as an indicator of latent infection. If the kidney is a source of
virus, and its presence is indicated by the donor being seropositive, we would expect a
positive correlation between seropositivity of the donor and subsequent CMV infec-
tion in the recipient, as demonstrated by virus isolation or serological rise. Such a
correlation should be particularly strong in recipients who develop a primary infec-
tion, i.e., who were seronegative before transplantation.
Table 2 shows the relationship ofthe donor's CF titer to the development ofCMV
infection in the recipient. Out of 32 patients, 21 became infected (66%). Eleven
seronegative donors provided kidneys for 12 recipients, ofwhom five became infected
(42%). On the other hand, 20 patients received kidneys from donors with titers > 1:4,
and 16 became infected (80%). This difference is significant (P = 0.03, Fisher's exact
test). The infected recipients also included those whose titer's were > 1:4 before
transplantation, and therefore may not have been at risk for primary infection.
Table 3 considers a recipient subgroup whose titers were all < 1:4 before opera-
tion. Within this group, those whose donor titers were < 1:4 became infected 30% of
the time (3/10), while those whose donor titers were > 1:4 were 83% infected
(10/12). This difference is statistically significant (P = 0.02) and is consistent with
the hypothesis that a source of virus in primary CMV infection is the transplanted
kidney.
It has been observed that the incubation period ofprimary infection with CMV is
around 2 months, and that in secondary infection it is longer (2). In our patient group,
all 13 seronegative patients who became infected did so within a 3-month postopera-
tive period, while four patients who developed their infection later than this had pre-
TABLE 2
Effect ofDonor's CMV-CF Titer on CMV Infection ofRecipient
Donor Recipient
CMV infection
Rising
No CMV titer CMV
Number Titer infection only Isolation Rate Rate
11 <1:4 7 0 5 42% 42%
4 1:4 3 3 1 57%)
1 1:8 0 0 2 100%
4 1:16 0 0 4 100% 80%
5 1:32 0 0 5 100%
2 1:64 1 0 1 50%)
27 1 1 3 18 66%
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TABLE 3
Effect ofDonor CF Status on CMV Infection in Seronegative Recipients
Recipient with preoperation titer < 1:4
Donor's No CMV CMV
CF titer infection infection Total
< 1:4 7 3 (30%) 10
> 1:4 2 10 (83%) 12
Total 9 13 (59%) 22
operative titers > 1:4 and were presumably secondarily infected. This gives some
assurance, but by no means certitude, that the seronegative patients were actually
seronegative, and not patients in whom antibody was undetectable and who may have
been harboring latent virus. We realize the limits of inferences from serological
studies, and the dangers ofover-interpretation. At best these data point to the kidney
as a possible source ofinfection in renal transplantation. This is a reasonable postu-
late, as the kidney is a frequent site oflatent CMV infection in man.
There were three seronegative patients out often who became infected, but whose
donors' CF titers were < 1:4. The following considerations may be made: (i) The
donors may have had low titers, which were not detected. (ii) The recipients may
have been infected from outside sources other than the donated kidney, suggesting
that the donated kidney is not the exclusive source of exogenous virus. The latter is
our present interpretation because "epidemics" of CMV infection in transplant
recipients (5) probably could not have been caused by virus in donated kidneys.
However, it is interesting that all three kidneys were from seronegative cadavers.
Conversely, six seronegative related live donors provided kidneys for six seronegative
recipients, and none became infected. This suggests that the poorer tissue matching
of cadaver donors (host versus graft reaction) might further increase the suscepti-
bility ofthe recipient to extrarenal sources ofvirus.
Two approaches are suggested by our results: (i) Look for latent virus in the
kidneys of seropositive individuals. This is now eminently feasible with development
of newer techniques of unmasking latent viruses, particularly herpesviruses. (ii)
Study the role ofimmunological rejection responses on the activation of virus infec-
tions. Experimental results pertaining to the latter point will be discussed next.
ENCHANCEMENT OF INFECTION BY
HOST VERSUS GRAFT REACTION
Enhancement of virus infection by immunological reactions is a topic ofincreasing
interest. Mouse leukemia virus was activated in inapparently infected mice by the
transfer of parenteral spleen cells to an F1 recipient, producing a graft versus host
reaction (14). Olding et al. (30) noted that virus could be activated when spleen cells
from inapparently infected mice were cultured on allogeneic but not syngeneic mouse
fibroblasts, and they found that activation occurred in immunologically stimulated B
lymphocytes.
We began with the hypothesis that one constant immunological reaction which
takes place in all renal transplantation is the host versus graft reaction. To study the
effect of this reaction on enhancement of a chronic infection or increasing suscepti-
bility to primary infection apart from the influence of renal failure, transfusions, and
immunosuppression, we felt that a rigorous test of the hypothesis could only be
achieved in an animal model.
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Five-week-old C3H He mice were inoculated ip with 2 x 105 PFU ofSmith strain
of mouse CMV. Five weeks later these C3H mice were given skin allografts from
normal 10-week-old BALB/C mice. Controls similarly infected consisted of C3H
mice which received no graft or an autograft. At periodic intervals, organs of each
mouse were individually titrated for virus content.
As shown in Fig. 2A, the proportion of infected spleens of allograft animals was
not significantly different from controls, but the geometric mean virus titers of posi-
tive spleens of grafted animals were consistently higher than the controls from the
first through the tenth day after grafting (P < 0.01, Wilcoxon rank sum test).
Similar data for the proportion of kidneys infected and mean virus titers ofinfected
kidneys are shown in Fig. 2B. Significant elevation of virus titers is again
demonstrated. Comparable results were obtained when recipient mice were infected
for 2 and 13 weeks prior to grafting.
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TABLE 4
Incidence ofCMV Infection after Renal Transplant in Seropositive and Seronegative Recipients
Infection rate
Total Seropositive Seronegative
Author (No.) (%) (No.) (%) (No.) (%)
Craigheadetal., 1967(8) 41 73% 24 91% 17 47%
Craighead, 1969(7) 53 60% 36 64% 17 53%
Andersen and Spencer, 1969 (2) 36 91% 31 97% 5 60%
Armstrong et al., 1971 (3) 6 100% 2 100% 4 100%
Spencer, 1974 (32) 100 86% 73 92% 27 70%
Lubyetal., 1974(24) 44 73% 12 ?73% 13 ?73%
Present series 32 66% 10 80% 22 59%
These experiments demonstrate that virus titers may be enhanced by a host versus
graft reaction, such as that which takes place following renal transplantation. They
do not indicate the mechanism of enhancement. Specific immune responses may be
impaired, facilitating viral replication in general, or a more direct reactivation of
latent virus in specific cells (such as B cells, as suggested by Olding et al. (30) ) may
take place. In any case, it is not unreasonable to assume that a similar process occurs
in man. These experiments also do not differentiate reactivation ofa latent or chronic
infection (secondary infection) from increased susceptibility to primary infection.
Evidence of 30% primary infection in recipients of seronegative cadaver kidneys sug-
gests that the latter mechanisms are also operative. Finally, these animal experi-
ments do not indicate how important the host versus graft mechanism is in producing
CMV in humans. They only demonstrate that it may be operative.
DISCUSSION
Primary infection with CMV in an adult can rarely be conclusively proven because
its presence is indicated by the absence ofantibody before infection. A negative find-
ing, particularly in the somewhat controversial arena of CMV serology (35), is
tenuous ground on which to diagnose a positive event. Further, authors have assumed
that most CMV infections following transplantation areofthe secondary or reactiva-
tion type (e.g., 2). Nevertheless, a review ofliterature and our own experience(Table
4) shows that a significant, though smaller, number of infections occurs in initially
seronegative subjects, and hence they are ofthe primary type. Primary infection im-
plies that the virus was transmitted from outside the patient.
An estimate oftheimportanceofvarious sources is presented in Table 5. From our
data, the infection rate for seronegative recipients who did not receive a kidney from
a seropositive, or putatively latently infected, donor was 30%. By exclusion, such an
individual was infected from a nonrenal exogenuous source. This represents only 23%
of the "primary" infections, and 14% of the total, but it may be an important factor
in the certain "epidemic" situations (5).
By comparison, when a seronegative recipient received a kidney from a seroposi-
tive donor, the risk ofinfection increased to 83%. Interestingly, the two seropositive
donors whose kidneys did not produce an infection in this group both had low CF
titers of 1:4. Infection from donated kidneys represented 77% ofthe "primary infec-
tions", or 47% ofthe total. Kidneys from seropositive donors, particularly those with
high antibody titers, must be considered a significant risk.
23HO ET AL.
TABLE 5
Quantitation ofRisk Factors in CMV Infection After Renal Transplant
Riska
A. Source ofvirus in primary infection
1. From non-renal source
Seronegative donor in seronegative recipient (3/10) 30%
Infecting seronegatives (3/13) 23%
Infecting total group (3/21) 14%
2. From donated kidney
Seropositive donor in seronegative recipient (10/12) 83%
Infecting seronegatives (10/13) 77%
Infecting total group (10/21) 47%
B. Depression ofhost resistance
1. Immunosuppression b
Role in total transplant group (RG:43%, TG:66%)c 65%
Role in seropositive group (RG:56%, TG:80%) 70%
Role in seronegative group (RG:20%, TG:59%) 34%
2. Steroids-nondetectable effect on CMV infection
3. Graft reaction-operative but not quantitated
4. Renal failure-probably none
aRisk is the calculated proportion ofinfection accounted for by the stated factor.
bImmunosuppression means that patients received a cytotoxic immunosuppresive drug such as azathio-
prine or cyclophosphamide.
cRG = rheumatology group; TG = transplant group.
Whether kidney donors should be screened routinely for their CMV CF titer is a
moot point. One would like to have more direct evidence that the kidneys ofsuch sub-
jects are infected, and one would like more data on the disease implications ofCMV
infection which in the majority ofcases now appear asymptomatic.
The risk due to immunosuppression can be assessed ifwe assume that the study of
immunosuppressed rheumatology patients (see Dowling et al., elsewhere in this
volume) isolated the factor of immunosuppression. CMV infection in the total renal
recipient group was 66%, while 43% of prospectively studied immunosuppressed
rheumatology patients developed infection. Thus 65% (0.43/0.66) ofthe infections in
the transplant recipients may be accounted for by immunosuppression. By the same
reasoning, immunosuppression could account for 70% of the infections in seroposi-
tive, and 34% in seronegative, transplant patients.
It is clear that immunosuppression is a predominant but not sufficient factor in
CMV infection. In primary infection, its role is less important. Immunosuppression
might partially explain why most of the CMV infections after renal transplantation
are secondary reactivation types.
The doses of azathioprine used in both groups are comparable. Persistent viruria
was common in patients on immunosuppression. None of the rheumatology patients
developed viremia, while 52% (12/21) of the infected in the transplant group had vi-
remia. None of our children who developed CMV infection after undergoing open-
heart surgery developed viremia either (see Armstrong et al., elsewhere in this
volume). The transplant patient may be subject to additional risk factors peculiar to
that group ofpatients.
One of these is immunological enhancement of CMV infection. We recently
showed that a host versus graft response enhanced murine CMV infection (37), and
Hirsch et al. (14) have shown that a graft versus host response enhanced mouse
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leukemia virus activity. Presumably these reactions may be mediated by the allo-
graft, although components of transfused blood may participate in these reactions
(19). We were, however, unable to demonstrate that risk ofCMV infection increases
with amounts ofblood transfused.
A number of other factors may be contributing to risk of infection, but their role
cannot be proven either because they are always present and cannot be studied
separately, or because by themselves they do not predispose to CMV, but they may
act synergistically with other factors. Two such factors are uremia and administra-
tion of steroids. Neither alone has been shown to facilitate CMV infection (32, 18,
and elsewhere in this volume). Uremia, however, almost invariably precedes trans-
plant surgery, and steroids are almost invariably administered with immunosup-
pressants so that it is difficult to rule out their contributory role.
SUMMARY
Cytomegalovirus infection is a frequent occurrence after renal transplantation.
Primary infections is caused by transmission of virus from the donated kidney,
particularly ifthe recipient is seronegative (nonimmune), and ifthe donor is seroposi-
tive (harbors virus). It can be shown that a small but significant risk of infection
arises from unknown, nonrenal, exogenuous sources. Blood may still be a source, al-
though units transfused could not be related to infection.
In mice chronically infected with mouse cytomegalovirus, skin allograft enhanced
virus titers. It can be assumed that host versus graft reaction following renal trans-
plant may similarly enhance or activate human CMV. Immunosuppressive drugs can
be shown to be particularly important in producing reactivation or secondary infec-
tion. However, it alone cannot explain the high rate ofinfection.
Note added in proof: Our evidence that the donated kidney may be a source of CMV infection was
published in M. Ho et al., New Eng. J. Med. 293, 1109-1112, 1975.
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